What is the recommended treatment regimen for an adult with moderate persistent asthma?

Treatment of Moderate Persistent Asthma in Adults

The preferred treatment for moderate persistent asthma in adults is low-to-medium-dose inhaled corticosteroids (ICS) combined with a long-acting beta2-agonist (LABA), with ICS-formoterol as the single maintenance and reliever therapy (SMART/MART) being the optimal regimen. 1

Preferred First-Line Regimen

Combination ICS-LABA therapy is the cornerstone of moderate persistent asthma management (Step 3 care):

• Low-to-medium-dose ICS + LABA is superior to doubling ICS doses alone for improving lung function, reducing symptoms, and preventing exacerbations 2
• The evidence supporting this combination is classified as Evidence A - the strongest level available 2
• ICS-formoterol as both maintenance and reliever therapy (MART) is specifically recommended as the preferred approach for moderate-severe asthma, as it further reduces severe exacerbations compared to fixed-dose regimens 1, 3

Why This Combination Works Best

Long-acting beta2-agonists added to ICS provide more effective asthma control than increasing ICS doses alone. The LABA may enhance the anti-inflammatory effects of corticosteroids through glucocorticoid receptor priming 2. Critically, LABAs should never be used as monotherapy - they must always be combined with ICS to avoid increased exacerbation risk and treatment failures 4, 1.

Alternative Treatment Options (When Preferred Therapy Cannot Be Used)

If ICS-LABA combination is not suitable, consider these alternatives in order:

1. Increase ICS to medium-dose range as monotherapy 2
2. Low-to-medium-dose ICS + leukotriene receptor antagonist (LTRA) such as montelukast 2
3. Low-to-medium-dose ICS + theophylline (requires serum level monitoring) 2

The evidence for these alternatives is weaker (Evidence B) compared to ICS-LABA combinations 2.

For Patients with Recurrent Severe Exacerbations

If the patient has a history of repeated emergency department visits, hospitalizations, or frequent oral corticosteroid courses:

• Increase ICS to medium-dose range AND add LABA 2
• This dual intensification approach reduces exacerbation risk more effectively than either strategy alone 2

Quick-Relief Medication

• Short-acting beta2-agonist (SABA) such as albuterol for acute symptom relief 1
• Using SABA more than 2 days per week (excluding pre-exercise use) indicates inadequate control and need for treatment intensification 1
• Exception: If using ICS-formoterol MART regimen, the same ICS-formoterol inhaler serves as both controller and reliever 3

Critical Safety Considerations

LABA Safety Warning: There have been concerns about increased severe exacerbations and deaths when LABAs are added to usual asthma therapy, particularly in certain populations including Black patients who may have genetic variations affecting LABA effectiveness 4. However, these risks are mitigated when LABAs are used appropriately in combination with ICS, never as monotherapy 4.

Monitoring and Adjustment

After initiating therapy:

• Assess control at each visit using validated tools
• Once full control is achieved, attempt to step down ICS dose while maintaining LABA 5
• If control is not achieved on medium-dose ICS-LABA, escalate to Step 4 (high-dose ICS-LABA) or consider adding a third agent such as a long-acting muscarinic antagonist 1, 3

What NOT to Do

• Do not use SABA alone as the only treatment for moderate persistent asthma
• Do not use LABA without concurrent ICS therapy 1
• Do not add a third controller medication (like LTRA) to ICS-LABA unless already on medium-to-high doses and still uncontrolled 2